TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00053053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Juven Supplement
Study: NCT01282268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: orally disintegrating tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally disintegrating tablet
Study: NCT01516320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Description: A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical Sleeve Gastrectomy
Description: A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
Study: NCT03991715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
Study: NCT02839707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01832376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided needle lavage
Description: A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
Study: NCT00060112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02989675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Description: Bolus of 10% dextrose 5mls/kg
Study: NCT03413566

Intervention type: OTHER
Intervention: Clinical diagnosis
Description: A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
Study: NCT02480842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloplastic free ROM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloplastic limited ROM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncoplastic free ROM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncoplastic limited ROM
Study: NCT03535103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-F®
Description: A single Subcutaneous injection, 225IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM001
Description: A single Subcutaneous injection, 225IU
Study: NCT02880189

Intervention type: DEVICE
Group type: OTHER
Intervention: Orbera Intragastric Balloon
Description: The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Ultrasound Guided Core Liver Biopsy
Study: NCT03576066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC NUC
Description: Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will receive placebo matching ABI-0731 tablets orally QD.
Study: NCT03521232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: enema given twice daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: enema given twice daily for 6 weeks
Study: NCT01474772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150-300 mg/day given in 3 divided doses as capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo capsules given in 3 divided doses
Study: NCT01131429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/d per os until proven disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
Study: NCT02289898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously
Study: NCT01131429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg/d per os as second-line treatment
Study: NCT04131205

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
Study: NCT01991080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback
Description: Patients will go through biofeedback sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback
Description: Patients will go through biofeedback sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wheatgerm juice
Description: Patient will drink wheatgerm juice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wheatgerm juice
Description: Patient will drink wheatgerm juice
Study: NCT01619059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Study: NCT03259503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03374267

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.
Study: NCT04030559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tosylate Monohydrate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo standard of care surgery
Study: NCT01619059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Saxagliptin
Description: Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
Study: NCT05430087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.
Description: All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
Study: NCT01444625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate
Description: High-flavanol chocolate, 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol-free chocolate
Description: Flavanol-free chocolate, 12 weeks
Study: NCT04092894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 20 mg
Description: Administration of oral Suvorexant 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Administration of oral placebo (same non-identifiable form as active comparator)
Study: NCT04549779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low volume interscalene brachial plexus block
Description: ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermediate volume interscalene brachial plexus block
Description: ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High volume interscalene brachial plexus block
Description: ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
Study: NCT01414023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Vision Task
Description: Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
Study: NCT01552551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment and education
Description: PA Healthy Steps program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Steps with Falls Case Management
Description: Counseling to ensure that participants receive a physician assessment and home safety check

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Steps in Motion
Description: Group exercise program
Study: NCT01497990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
Study: NCT03692377

Intervention type: DEVICE
Intervention: Virtual Reality
Description: Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
Study: NCT02498886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
Study: NCT02289898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03809117

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biofire Film Array Gastrointestinal Panel
Description: The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biofire Film Array Gastrointestinal Panel
Description: The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
Study: NCT04231864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given orally (PO)
Study: NCT05430087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.
Description: All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.
Description: All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
Study: NCT01961609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab was supplied in 150mg pre-filled syringes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab was supplied in 150mg pre-filled syringes.
Study: NCT00606333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVO™ Sirolimus-eluting Coronary Stent System
Description: Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
Description: Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Study: NCT03764020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule/placebo comparator
Description: 3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin/experimental
Description: Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
Study: NCT03132688

Intervention type: DRUG
Intervention: Propofol
Description: Intravenous administration with dose of 100-200mcg/kg/min
Study: NCT04305197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study: NCT03627637

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy nuts
Description: Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.